Deltec Asset Management LLC Sells 79,400 Shares of Boston Scientific Corporation $BSX

Key Points

• Deltec Asset Management cut its Boston Scientific stake by 92.4% in the third quarter, selling 79,400 shares and retaining 6,500 shares valued at approximately $284,000.
• Boston Scientific insiders showed buying activity, including CEO Michael Mahoney’s purchase of 186,240 shares worth about $9 million; insiders bought roughly $9.4 million in stock over the past three months.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $68.07, despite several recent target-price reductions. The company also exceeded its latest quarterly EPS and revenue estimates.

Deltec Asset Management LLC cut its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 92.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,500 shares of the medical equipment provider's stock after selling 79,400 shares during the quarter. Deltec Asset Management LLC's holdings in Boston Scientific were worth $284,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Plimoth Trust Co. LLC purchased a new position in Boston Scientific during the third quarter worth $354,000. Apollon Wealth Management LLC raised its stake in shares of Boston Scientific by 46.9% in the third quarter. Apollon Wealth Management LLC now owns 47,415 shares of the medical equipment provider's stock valued at $2,070,000 after acquiring an additional 15,134 shares during the period. Purewater Capital LLC bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $1,604,000. Kingswood Wealth Advisors LLC boosted its stake in shares of Boston Scientific by 14.4% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 12,315 shares of the medical equipment provider's stock worth $538,000 after purchasing an additional 1,553 shares during the period. Finally, Broadway Wealth Solutions Inc. boosted its stake in shares of Boston Scientific by 9.9% during the 3rd quarter. Broadway Wealth Solutions Inc. now owns 7,562 shares of the medical equipment provider's stock worth $330,000 after purchasing an additional 681 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Mahoney purchased 186,240 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BSX. Oppenheimer cut their price target on shares of Boston Scientific from $85.00 to $65.00 and set an "outperform" rating on the stock in a report on Monday, September 21st. Citigroup decreased their price objective on shares of Boston Scientific from $50.00 to $48.00 and set a "neutral" rating for the company in a research note on Monday, October 5th. Piper Sandler dropped their target price on Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. Robert W. Baird set a $56.00 target price on Boston Scientific in a research report on Thursday, July 30th. Finally, BTIG Research cut their target price on Boston Scientific from $60.00 to $56.00 and set a "buy" rating on the stock in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $68.07.

Boston Scientific Trading Down 0.2%

NYSE BSX opened at $45.60 on Tuesday. The company's 50-day moving average price is $45.54 and its 200-day moving average price is $58.24. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a market cap of $66.08 billion, a PE ratio of 18.46, a PEG ratio of 1.10 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.